Search
Research
Modelling the seasonal epidemics of respiratory syncytial virus in young childrenThis paper describes a mathematical model used to predict when an epidemic of respiratory syncytial virus (RSV) will occur so that preventive measures, such...
Research
Infection is the major component of the disease burden in Aboriginal and non-Aboriginal Australian children: a population-based studyInfection accounts for the majority of pediatric mortality and morbidity in developing countries, but there are limited data on the infectious diseases...
Research
Evaluating the use and effectiveness of passive immunization in reducing RSV-associated morbidity in high risk infantsHannah Tom Moore Snelling OAM BSc (Hons) GradDipClinEpi PhD BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Diseases Research Head, Infectious
Research
The PneuCaPTIVE studyChristopher Deborah Blyth Lehmann MBBS (Hons) DCH FRACP FRCPA PhD AO, MBBS, MSc Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases;
Research
Immunisation and pregnancy - who, what, when and why?Recommending vaccination to pregnant women is important as evidence shows they are more likely to get vaccinated if their healthcare provider advises it
Research
Assessment of on-time vaccination coverage in population subgroups: A record linkage cohort studyOn-time coverage of the 2-4-6 month schedule is only 50-60% across specific population subgroups representing a significant avoidable public health risk
Research
Effectiveness of seasonal trivalent influenza vaccination against hospital-attended acute respiratory infections in pregnant womenInfluenza vaccination during pregnancy was associated with significantly fewer hospital attendances for ARI in pregnant women
Research
COVID-19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non-malignant haematological conditions: Australian and New Zealand Children’s Haematology/Oncology Group consensus statementThe Australian Technical Advisory Group on Immunisation and New Zealand Ministry of Health recommend all children aged ≥ 5 years receive either of the two mRNA COVID-19 vaccines: Comirnaty (Pfizer), available in both Australia and New Zealand, or Spikevax (Moderna), available in Australia only. Both vaccines are efficacious and safe in the general population, including children. Children and adolescents undergoing treatment for cancer and immunosuppressive therapy for non-malignant haematological conditions are particularly vulnerable, with an increased risk of severe or fatal COVID-19.
Research
Invasive fungal disease in children with solid tumors: An Australian multicenter 10-year reviewInvasive fungal disease (IFD) occurs less frequently during treatment for solid compared to hematological malignancies in children, and risk groups are poorly defined. Retrospective national multicenter cohort data (2004-2013) were analyzed to document prevalence, clinical characteristics, and microbiology of IFD.
Research
“Our kids are our future”: Barriers and facilitators to vaccine uptake and timeliness among Aboriginal children younger than five years in Boorloo (Perth), Western AustraliaRates of several vaccine preventable diseases, and associated hospitalisation, are higher among Aboriginal and/or Torres Strait Islander children than non-Indigenous children. Western Australia has among the lowest childhood vaccine coverage in Australia, particularly among Aboriginal and/or Torres Strait Islander children. Delayed vaccination is also more common in this population. This project aimed to understand the barriers and facilitators to vaccine uptake and timeliness among Aboriginal and/or Torres Strait Islander children aged under five years in Boorloo (Perth).